Cerus Co. (NASDAQ:CERS) Director Sells $35,600.00 in Stock

Cerus Co. (NASDAQ:CERS - Get Free Report) Director Eric Bjerkholt sold 20,000 shares of the firm's stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $1.78, for a total transaction of $35,600.00. Following the transaction, the director now directly owns 162,133 shares in the company, valued at $288,596.74. The trade was a 10.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Cerus Stock Performance

NASDAQ CERS traded up $0.09 during trading hours on Monday, reaching $1.80. 1,161,475 shares of the company were exchanged, compared to its average volume of 1,274,255. The stock has a market capitalization of $334.29 million, a P/E ratio of -16.36 and a beta of 1.24. The company has a quick ratio of 1.92, a current ratio of 2.59 and a debt-to-equity ratio of 1.19. Cerus Co. has a 1 year low of $1.38 and a 1 year high of $2.59. The business's 50 day simple moving average is $1.75 and its 200-day simple moving average is $1.91.

Wall Street Analyst Weigh In

Separately, Stifel Nicolaus cut their target price on Cerus from $6.00 to $3.00 and set a "buy" rating on the stock in a research note on Thursday, October 17th.

Institutional Investors Weigh In On Cerus

A number of hedge funds have recently modified their holdings of CERS. Geode Capital Management LLC increased its position in Cerus by 1.6% in the third quarter. Geode Capital Management LLC now owns 4,415,453 shares of the biotechnology company's stock worth $7,685,000 after buying an additional 69,950 shares during the last quarter. State Street Corp grew its stake in shares of Cerus by 2.2% during the 3rd quarter. State Street Corp now owns 3,738,893 shares of the biotechnology company's stock worth $6,506,000 after acquiring an additional 79,505 shares during the period. Charles Schwab Investment Management Inc. increased its holdings in Cerus by 0.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,754,540 shares of the biotechnology company's stock worth $3,053,000 after acquiring an additional 8,707 shares during the last quarter. Barclays PLC raised its stake in Cerus by 16.2% in the 3rd quarter. Barclays PLC now owns 1,575,049 shares of the biotechnology company's stock valued at $2,740,000 after acquiring an additional 219,755 shares during the period. Finally, Hood River Capital Management LLC lifted its holdings in Cerus by 390.4% during the second quarter. Hood River Capital Management LLC now owns 1,469,754 shares of the biotechnology company's stock valued at $2,587,000 after purchasing an additional 1,170,060 shares during the last quarter. Institutional investors own 78.37% of the company's stock.

Cerus Company Profile

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.